6:54 PM
 | 
Dec 11, 2012
 |  BC Extra  |  Top Story

Isis, AstraZeneca in cancer deal

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to discover antisense therapeutics against four undisclosed cancer targets from AstraZeneca. Isis also granted AstraZeneca exclusive rights to develop and commercialize ISIS-STAT3Rx, an antisense inhibitor of signal transducer and activator of transcription 3 (STAT3)...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >